Imperial College London
Alternate

ProfessorKathMaitland

Faculty of Medicine, Department of Surgery & Cancer

Professor of Tropical Paediatric Infectious Disease
 
 
 
//

Contact

 

k.maitland CV

 
 
//

Location

 

Based full-time at KEMRI/Wellcome Programme, KenyaQueen Elizabeth and Queen Mary HospitalSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Taylor:2023:10.1016/s1473-3099(22)00658-2,
author = {Taylor, WR and Olupot-Olupot, P and Onyamboko, MA and Peerawaranun, P and Weere, W and Namayanja, C and Onyas, P and Titin, H and Baseke, J and Muhindo, R and Kayembe, DK and Ndjowo, PO and Basara, BB and Bongo, GS and Okalebo, CB and Abongo, G and Uyoga, S and Williams, TN and Taya, C and Dhorda, M and Tarning, J and Dondorp, AM and Waithira, N and Fanello, C and Maitland, K and Mukaka, M and Day, NJP},
doi = {10.1016/s1473-3099(22)00658-2},
journal = {The Lancet Infectious Diseases},
pages = {471--483},
title = {Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial},
url = {http://dx.doi.org/10.1016/s1473-3099(22)00658-2},
volume = {23},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BackgroundWHO recommends gametocytocidal, single low-dose primaquine for blocking the transmission of Plasmodium falciparum; however, safety concerns have hampered the implementation of this strategy in sub-Saharan Africa. We aimed to investigate the safety of age-dosed, single low-dose primaquine in children from Uganda and the Democratic Republic of the Congo.MethodsWe conducted this randomised, double-blind, placebo-controlled, non-inferiority trial at the Mbale Regional Referral Hospital, Mbale, Uganda, and the Kinshasa Mahidol Oxford Research Unit, Kinshasa, Democratic Republic of the Congo. Children aged between 6 months and 11 years with acute uncomplicated P falciparum infection and haemoglobin concentrations of at least 6 g/dL were enrolled. Patients were excluded if they had a comorbid illness requiring inpatient treatment, were taking haemolysing drugs for glucose-6-phosphate dehydrogenase (G6PD) deficiency, were allergic to the study drugs, or were enrolled in another clinical trial. G6PD status was defined by genotyping for the G6PD c.202T allele, the cause of the G6PD-deficient A− variant. Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether–lumefantrine or dihydroartemisinin–piperaquine, dosed by bodyweight. Randomisation was stratified by age and G6PD status. The primary endpoint was the development of profound (haemoglobin <4 g/dL) or severe (haemoglobin <5 g/dL) anaemia with severity features, within 21 days of treatment. Analysis was by intention to treat. The sample size assumed an incidence of 1·5% in the placebo group and a 3% non-inferiority margin. The trial is registered at ISRCTN, 11594437, and is closed to new participants.FindingsParticipants were recruited at the Mbale Regional Referral Hospital between Dec 18, 2017, and Oct 7, 2019, and at the Kinshasa Mahidol Oxford Research Unit between July 17, 2017, and Oct 5, 2019. 4620 patients were assessed
AU  - Taylor,WR
AU  - Olupot-Olupot,P
AU  - Onyamboko,MA
AU  - Peerawaranun,P
AU  - Weere,W
AU  - Namayanja,C
AU  - Onyas,P
AU  - Titin,H
AU  - Baseke,J
AU  - Muhindo,R
AU  - Kayembe,DK
AU  - Ndjowo,PO
AU  - Basara,BB
AU  - Bongo,GS
AU  - Okalebo,CB
AU  - Abongo,G
AU  - Uyoga,S
AU  - Williams,TN
AU  - Taya,C
AU  - Dhorda,M
AU  - Tarning,J
AU  - Dondorp,AM
AU  - Waithira,N
AU  - Fanello,C
AU  - Maitland,K
AU  - Mukaka,M
AU  - Day,NJP
DO  - 10.1016/s1473-3099(22)00658-2
EP  - 483
PY  - 2023///
SN  - 1473-3099
SP  - 471
TI  - Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial
T2  - The Lancet Infectious Diseases
UR  - http://dx.doi.org/10.1016/s1473-3099(22)00658-2
UR  - https://www.sciencedirect.com/science/article/pii/S1473309922006582?via%3Dihub
UR  - http://hdl.handle.net/10044/1/100399
VL  - 23
ER  -
Download